NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP
Harvard Bioscience, Inc. HBIO
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$86.5M
▼ 8.1% vs FY2024
EPS · FY25
$-1.28
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-147.1%
Net margin · FY25
-65.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 86.5M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 66 cents on every revenue dollar this year.
Per share
USD -1.28
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-147.1%
Return on equity, FY2025
ROE
Operating margin-56.1%
Net margin-65.5%
Return on assets-54.9%
Each USD of equity lost 147 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−3.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−8.6%
−3.3%
−2.2%
−1.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+13.5%
Change, 10 years+31.6%
The share count grew 13% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 80.1M
total assets, end of FY2025
Total assetsUSD 80.1M
EquityUSD 13.7M
CashUSD 8.6M
Gross debtUSD 35.9M
Net debtUSD 27.3M
Current ratio2.20×
Net debt stands at 198% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−1.28
−0.28
−0.08
−0.23
−0.01
−0.20
−0.12
−0.08
−0.02
−0.13
−0.57
0.07
−0.06
0.08
0.13
0.65
0.24
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−147.1
−18.2
−4.7
−12.2
−0.4
−9.9
−5.7
−3.6
−1.1
−5.8
−22.0
2.5
−1.8
2.4
4.1
23.0
9.6
Shares out B
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.03
0.03
0.03
0.03
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed